Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-modifying drugs.

Leon A Simons1, David R Sullivan

  • 1University of South Wales, Lipid Research Department, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia. L.Simons@notes.med.unsw.edu.au

The Medical Journal of Australia
|March 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling novel biomarkers for diabetes-related complications through large-scale proteomics analysis: A FIELD sub-study.

Journal of diabetes and its complications·2026
Same author

Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy.

Diabetes research and clinical practice·2026
Same author

Corrigendum to: "Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations" [Heart Lung Circ. 32(3) (2023) 287-296.].

Heart, lung & circulation·2026
Same author

Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial.

The lancet. Diabetes & endocrinology·2025
Same author

Author reply.

Internal medicine journal·2025
Same author

Spot urine is a suitable matrix for measurement of copeptin.

Clinical chemistry and laboratory medicine·2025
Same journal

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

The Medical journal of Australia·2026
Same journal

Striving for Racial Equity in Oral Cancer Research: A Case Study.

The Medical journal of Australia·2026
Same journal

Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

The Medical journal of Australia·2026
Same journal

Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data.

The Medical journal of Australia·2026
Same journal

Drivers of Vaccine Uptake for Aboriginal and Torres Strait Islander Children to Inform Tailored Strategies: A Qualitative Study Exploring Health Service Provider Perspective.

The Medical journal of Australia·2026
Same journal

Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments.

The Medical journal of Australia·2026
See all related articles

High low-density-lipoprotein cholesterol (LDL-C) increases heart disease risk. Statins effectively lower LDL-C, preventing cardiovascular events and strokes, with benefits seen at lower levels.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Elevated low-density-lipoprotein cholesterol (LDL-C) is a primary cause of coronary heart disease and ischemic stroke.
  • Statin therapies have demonstrated efficacy in placebo-controlled trials for cardiovascular disease prevention by lowering LDL-C.

Purpose of the Study:

  • To review the role of LDL-C in cardiovascular disease.
  • To discuss the benefits of lowering LDL-C concentrations, including target levels and pharmacological interventions.
  • To highlight treatment strategies for hyperlipidaemia and associated risks.

Main Methods:

  • Review of placebo-controlled intervention studies on statin drugs.
  • Analysis of evidence supporting specific LDL-C target concentrations.

Related Experiment Videos

  • Examination of pharmacological treatment options for hyperlipidaemia.

    • Main Results:

    • Statin use provides clear evidence of cardiovascular disease prevention.
    • Achieving LDL-C concentrations below 2.5 mmol/L, or even lower, is supported by recent trials.
    • Monotherapy is effective for predominant hypercholesterolaemia and hypertriglyceridaemia; combination therapy may be needed for severe or mixed cases.

    Conclusions:

    • Pharmacological treatment is indicated for patients at high absolute risk of cardiovascular events.
    • While generally safe, lipid-modifying medications require caution due to potential side effects like muscle or liver dysfunction and drug interactions.